Darktrace brought a genuinely different idea to cybersecurity: use unsupervised machine learning to model the normal “pattern of life” for every user, device, and network segment — then catch anomalies in real time without signatures or rules.
The company’s Enterprise Immune System learns what’s normal across an organization’s digital environment. When something deviates — an employee accessing files they’ve never touched, a server communicating with an unusual external IP — Darktrace flags it and can respond autonomously through its Antigena module.
Antigena takes surgical action: slowing connections, blocking specific ports, or quarantining devices — all without disrupting normal business operations. It’s designed to buy time while human analysts investigate, and it works at machine speed during fast-moving attacks like ransomware.
Darktrace covers email, network, cloud, IoT, and industrial control systems. The company went public on the London Stock Exchange in 2021 and was later acquired by Thoma Bravo for $5.3 billion. Over 8,800 organizations worldwide use Darktrace to detect threats that rule-based systems miss entirely.
